ArticleCurrent fungal infection reports2009
Genetic Basis of Antifungal Drug Resistance.
Article in Current fungal infection reports, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Machine learning identifies novel signatures of antifungal drug resistance in Saccharomycotina yeasts.PLoS genetics · 2026Article
- Stress-driven emergence of heritable non-genetic drug resistance.Research square · 2025Article
- International consensuses and guidelines on diagnosing and managing fungal endophthalmitis by the Asia-Pacific Vitreo-retina Society (APVRS), the Academy of the Asia-Pacific Professors of Ophthalmology (AAPPO), and the Asia-Pacific Society of Ocular Inflammation and Infection (APSOII).Eye and vision (London, England) · 2025Review
- Emergence of invasive candidiasis with multipleFrontiers in microbiology · 2025Article
- Exploring the frontiers of therapeutic breadth of antifungal peptides: A new avenue in antifungal drugs.Journal of industrial microbiology & biotechnology · 2024Review
- Ebselen: A Promising Repurposing Drug to Treat Infections Caused by Multidrug-Resistant Microorganisms.Interdisciplinary perspectives on infectious diseases · 2024Review
- Mechanisms of azole antifungal resistance in clinical isolates of Candida tropicalis.PloS one · 2022Article
- Epidemiological Characterization of Clinical Fungal Isolates from Pauls Stradinš Clinical University Hospital, Latvia: A 4-Year Surveillance Report.Life (Basel, Switzerland) · 2021Article
- Modulation of ERG Genes Expression in Clinical Isolates of Candida tropicalis Susceptible and Resistant to Fluconazole and Itraconazole.Mycopathologia · 2020Article
- Cytological and Gene Profile Expression Analysis Reveals Modification in Metabolic Pathways and Catalytic Activities Induce Resistance inInternational journal of molecular sciences · 2020Article
- Broad-spectrum antifungal activities and mechanism of drimane sesquiterpenoids.Microbial cell (Graz, Austria) · 2020Article
- Article
- The global regulator Ncb2 escapes from the core promoter and impacts transcription in response to drug stress in Candida albicans.Scientific reports · 2017Article
- An Update onFrontiers in microbiology · 2017Review
- Fatal Cases of Bloodstream Infection by Fusarium solani and Review of Published Literature.Mycopathologia · 2016Review
- Adhesion-dependent rupturing of Saccharomyces cerevisiae on biological antimicrobial nanostructured surfaces.Journal of the Royal Society, Interface · 2015Article
- Disruption of the transcriptional regulator Cas5 results in enhanced killing of Candida albicans by Fluconazole.Antimicrobial agents and chemotherapy · 2014Article
- Pivotal role for a tail subunit of the RNA polymerase II mediator complex CgMed2 in azole tolerance and adherence in Candida glabrata.Antimicrobial agents and chemotherapy · 2014Article
- UPC2 is universally essential for azole antifungal resistance in Candida albicans.Eukaryotic cell · 2014Article
- Mechanisms of Candida biofilm drug resistance.Future microbiology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Antifungal resistance caused by mutations of the drug target, overexpression of the drug target, and drug efflux by the upregulation of transporters is increasingly common. Recently our understanding of fungal drug resistance has been advanced by the identification of three key transcriptional regulators of resistance: Tac1p, Upc2p, and Mrr1p. The discovery of hyperactive variants of these regulators in resistant clinical isolates confirms the importance of transcriptional regulation in the development of antifungal resistance. Alternative mechanisms of drug resistance including aneuploidy and biofilm formation have recently been documented in fungi; as well as the phenomenon of drug tolerance. Characterization of the transcriptional regulation of fungal drug resistance and the identification of novel mechanisms of resistance has implications for current therapy and for the development of future antifungal drugs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.